Source: Cardiovascular Pathology. Conference titles: International Vascular Biology Meeting. Unidade: FM
Subjects: DOENÇA PULMONAR OBSTRUTIVA CRÔNICA (PATOLOGIA), HIPERTENSÃO, ATIVAÇÃO DE PLAQUETAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BYDLOWSKI, Sergio e LOPES, Augusto. Enhanced tyrosine-phosphorylation of platelet substrates including PP6-C-SRC and PP125FAK is indicative of endogenous platelet activation in pulmonary vaso-occlusive disease. Cardiovascular Pathology. New York: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 02 out. 2024. , 2004APA
Bydlowski, S., & Lopes, A. (2004). Enhanced tyrosine-phosphorylation of platelet substrates including PP6-C-SRC and PP125FAK is indicative of endogenous platelet activation in pulmonary vaso-occlusive disease. Cardiovascular Pathology. New York: Faculdade de Medicina, Universidade de São Paulo.NLM
Bydlowski S, Lopes A. Enhanced tyrosine-phosphorylation of platelet substrates including PP6-C-SRC and PP125FAK is indicative of endogenous platelet activation in pulmonary vaso-occlusive disease. Cardiovascular Pathology. 2004 ; 13 S122.[citado 2024 out. 02 ]Vancouver
Bydlowski S, Lopes A. Enhanced tyrosine-phosphorylation of platelet substrates including PP6-C-SRC and PP125FAK is indicative of endogenous platelet activation in pulmonary vaso-occlusive disease. Cardiovascular Pathology. 2004 ; 13 S122.[citado 2024 out. 02 ]
